CA2961107C - A method and a device for producing nanoparticles - Google Patents

A method and a device for producing nanoparticles Download PDF

Info

Publication number
CA2961107C
CA2961107C CA2961107A CA2961107A CA2961107C CA 2961107 C CA2961107 C CA 2961107C CA 2961107 A CA2961107 A CA 2961107A CA 2961107 A CA2961107 A CA 2961107A CA 2961107 C CA2961107 C CA 2961107C
Authority
CA
Canada
Prior art keywords
pressure
nozzle
mixture
fluid
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2961107A
Other languages
English (en)
French (fr)
Other versions
CA2961107A1 (en
Inventor
Edward Haeggstrom
Jouko Yliruusi
Kai Falck
Heikki Raikkonen
Jenni PESSI
Ilkka LASSILA
Antti Merilainen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanoform Finland Oyj
Original Assignee
Nanoform Finland Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanoform Finland Oyj filed Critical Nanoform Finland Oyj
Publication of CA2961107A1 publication Critical patent/CA2961107A1/en
Application granted granted Critical
Publication of CA2961107C publication Critical patent/CA2961107C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/02—Crystallisation from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/04—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/008—Processes carried out under supercritical conditions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Optics & Photonics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Steroid Compounds (AREA)
CA2961107A 2014-10-06 2015-10-05 A method and a device for producing nanoparticles Active CA2961107C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20140266 2014-10-06
FI20140266A FI20140266A7 (fi) 2014-10-06 2014-10-06 Menetelmä ja laite nanopartikkeleiden valmistamiseksi
PCT/FI2015/050664 WO2016055696A1 (en) 2014-10-06 2015-10-05 A method and a device for producing nanoparticles

Publications (2)

Publication Number Publication Date
CA2961107A1 CA2961107A1 (en) 2016-04-14
CA2961107C true CA2961107C (en) 2023-01-03

Family

ID=54540113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2961107A Active CA2961107C (en) 2014-10-06 2015-10-05 A method and a device for producing nanoparticles

Country Status (10)

Country Link
US (1) US10098842B2 (cg-RX-API-DMAC7.html)
EP (1) EP3204150B1 (cg-RX-API-DMAC7.html)
JP (1) JP6599995B2 (cg-RX-API-DMAC7.html)
CA (1) CA2961107C (cg-RX-API-DMAC7.html)
DK (1) DK3204150T3 (cg-RX-API-DMAC7.html)
ES (1) ES2969055T3 (cg-RX-API-DMAC7.html)
FI (2) FI20140266A7 (cg-RX-API-DMAC7.html)
PL (1) PL3204150T3 (cg-RX-API-DMAC7.html)
PT (1) PT3204150T (cg-RX-API-DMAC7.html)
WO (1) WO2016055696A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105641968B (zh) * 2016-01-07 2018-04-17 中国原子能科学研究院 一种具有在线光谱监测功能的超临界流体络合反应装置
FI127408B (en) 2016-09-29 2018-05-15 Nanoform Finland Oy Device, method and equipment for solubility testing
EP3706893B1 (en) * 2017-11-09 2021-09-29 BLH Ecology Concepts, L.L.C. Process to produce nanoparticles
CN111012671B (zh) * 2019-11-25 2022-07-05 上海强德食品科技有限公司 一种微胶囊的物理制备方法
CN111215002B (zh) * 2020-01-20 2021-08-10 中南大学 高温高压超临界二氧化碳反应釜
FI129026B (en) * 2020-01-29 2021-05-31 Nanoform Finland Oy System and method for producing particles of organic substances
EP3884930A1 (en) 2020-03-23 2021-09-29 Bayer AG Nano-dry-melting
CN111721495B (zh) * 2020-06-16 2022-02-08 中国人民解放军国防科技大学 一种新型纳米粒子平面激光散射实验的粒子生成装置
SI4489884T1 (sl) 2023-01-18 2025-12-31 Nanoform Finland Oyj Postopek za kristalizacijo zdravilnih učinkovin
AU2024209240A1 (en) 2023-01-18 2025-07-10 Helm Pharmaceuticals Gmbh Crystalline nanoparticles comprising enzalutamide
WO2025125509A1 (en) 2023-12-12 2025-06-19 Targtex S.A. Chemotherapeutic agent and compositions
AU2025209171A1 (en) 2024-01-18 2026-05-28 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide
WO2025262137A1 (en) 2024-06-21 2025-12-26 Nanoform Finland Oyj Formulations comprising crystalline nanosized encorafenib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102124B2 (ja) * 1985-12-27 1994-12-14 日本分光工業株式会社 超臨界流体による試料の分離回収方法
JP2774349B2 (ja) * 1990-03-17 1998-07-09 株式会社神戸製鋼所 微粒の製造方法
ES2306452T3 (es) 1995-10-17 2008-11-01 Jagotec Ag Aporte de farmacos insolubles.
EP0885038B1 (en) 1996-03-01 2011-06-15 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
AU8118298A (en) * 1997-06-20 1999-01-04 Smithkline Beecham Plc Treatment of a substance with a dense fluid (e.g. with a supercritical fluid
WO1999065469A2 (en) 1998-06-19 1999-12-23 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
FR2802445B1 (fr) * 1999-12-15 2002-02-15 Separex Sa Procede et dispositif de captage de fines particules par piegeage au sein d'un melange solide de type neige carbonique
WO2004110603A2 (en) 2003-06-03 2004-12-23 Ferro Corporation Method for preparation of particles from solution-in-supercritical fluid or compressed gas emulsions
US7754243B2 (en) 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
GB0525852D0 (en) * 2005-12-20 2006-02-01 Accentus Plc Crystallisation apparatus and process
JP2007301534A (ja) 2006-05-15 2007-11-22 Ebara Corp 微細化装置
US8585943B2 (en) * 2007-12-07 2013-11-19 Xspray Microparticles Ab Method and arrangement for the production of particles
JP5933234B2 (ja) * 2011-11-24 2016-06-08 国立大学法人東北大学 微粒子作製装置

Also Published As

Publication number Publication date
JP2017536983A (ja) 2017-12-14
EP3204150A1 (en) 2017-08-16
ES2969055T3 (es) 2024-05-16
EP3204150B1 (en) 2023-11-29
JP6599995B2 (ja) 2019-10-30
PT3204150T (pt) 2024-03-04
FI3204150T3 (fi) 2023-12-04
US10098842B2 (en) 2018-10-16
US20170231914A1 (en) 2017-08-17
CA2961107A1 (en) 2016-04-14
PL3204150T3 (pl) 2024-05-13
WO2016055696A1 (en) 2016-04-14
DK3204150T3 (da) 2024-03-04
FI20140266A7 (fi) 2016-04-07

Similar Documents

Publication Publication Date Title
US10098842B2 (en) Method and a device for producing nanoparticles
Thakur et al. Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process
Rodrigues et al. Microcomposites theophylline/hydrogenated palm oil from a PGSS process for controlled drug delivery systems
JP3986086B2 (ja) 近臨界および超臨界反溶媒を用いる粒子析出方法および被覆方法
KR100508910B1 (ko) 불용성약물방출
Türk et al. Formation and stabilization of submicron particles via rapid expansion processes
Padrela et al. Tuning physicochemical properties of theophylline by cocrystallization using the supercritical fluid enhanced atomization technique
Duarte et al. Preparation of ethyl cellulose/methyl cellulose blends by supercritical antisolvent precipitation
Sievers et al. Micronization of water-soluble or alcohol-soluble pharmaceuticals and model compounds with a low-temperature Bubble Dryer®
Tandya et al. Supercritical fluid micronization techniques for gastroresistant insulin formulations
Cai et al. Supercritical fluid assisted atomization introduced by hydrodynamic cavitation mixer (SAA-HCM) for micronization of levofloxacin hydrochloride
Barrett et al. Increasing the dissolution rate of itraconazole processed by gas antisolvent techniques using polyethylene glycol as a carrier
Khapli et al. Supercritical CO2 based processing of amorphous fluoropolymer Teflon-AF: surfactant-free dispersions and superhydrophobic films
Reverchon et al. Crystalline microparticles of controlled size produced by supercritical-assisted atomization
Akbari et al. Preparation and characterization of solid lipid nanoparticles through rapid expansion of supercritical solution
Luo et al. Rapid and sustainable production of nano and micro medicine crystals via freeze-dissolving technology
Bakhbakhi et al. Supercritical antisolvent synthesis of fine griseofulvin particles
Gadermann et al. Formation of naproxen–polylactic acid nanoparticles from supercritical solutions and their characterization in the aerosol phase
Oliveira et al. Evaluation of the potential use of laminar extrudates on stabilizing micronized coumarin particles by supercritical fluids (RESS)—study of different RESS processing variables and mode of operation
Caputo et al. Use of urea as habit modifier in the supercritical antisolvent micronization of sulfathiazole
Danan et al. Critical gases for critical issues: CO2 technologies for oral drug delivery
Tenorio et al. On the selection of limiting hydrodynamic conditions for the supercritical antisolvent (SAS) process
Chauhan et al. Micronization of BCS Class–II Drugs by Various Approaches for Solubility Enhancement–A Review
Lin et al. Producing nanoparticles using precipitation with compressed antisolvent
Sheng et al. Continuous and scalable process for the production of hollow crystals of a poorly water-soluble active pharmaceutical ingredient for dissolution enhancement and inhaled delivery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200806

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240923

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240923

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250922

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250922